KAMERYN FEVELLA: Open Payments
NPI 1003316423 · SAINT FRANCISVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$897 in 63 payments from 15 companies in 2025. Trend: 2023 $836 · 2024 $657 · 2025 $897
Food & beverage: $897
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $190 |
| Novo Nordisk Inc | 11 | $148 |
| GlaxoSmithKline, LLC. | 8 | $145 |
| PFIZER INC. | 6 | $104 |
| Phathom Pharmaceuticals, Inc. | 5 | $48 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $42 |
| Organon LLC | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Boston Scientific Corporation | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
Products named: VRAYLAR, TRELEGY ELLIPTA, ELIQUIS, Wegovy, VOQUEZNA, Ozempic, Rybelsus, Kerendia.
Industry payments across LA — which companies pay providers there.
